Genome Protection, Inc. SAFE (Simple Agreement for Future Equity)Safe (Simple Agreement for Future Equity) • August 14th, 2018 • Cleveland Biolabs Inc • Services-commercial physical & biological research
THIS SIMPLE AGREEMENT FOR FUTURE EQUITY (THIS “AGREEMENT”), DATED AS OF August 10, 2018, CERTIFIES THAT in exchange for the payment in instalments by Norma Investments Limited, a British Virgin Islands company (the “Investor”) of up to US$30,000,000.00 (the “Purchase Amount”) as specified herein, Genome Protection, Inc., a Delaware corporation (the “Company”), hereby grants to the Investor the right to certain shares of the Company’s capital stock, subject to the terms set forth below. The first installment of the Purchase Amount of US$10,500,000.00 is payable within 3 business days from the date of execution of this Agreement. The subsequent installments shall be made in the amount and within the timeframe determined in a drawdown request by the Company made after the corresponding decision of the Board of Directors, provided the Investor shall be given at least 10 business days’ prior written notice of the requirement to make any payment. It is preliminarily intended that one further
DIRECTOR DESIGNATION AGREEMENTDirector Designation Agreement • August 14th, 2018 • Cleveland Biolabs Inc • Services-commercial physical & biological research • Delaware
This Director Designation Agreement, dated as of August 10, 2018 (this “Agreement”), is hereby entered into by and among Genome Protection, Inc., a Delaware corporation (the “Company”), Everon BioSciences, Inc., a corporation organized and existing under the laws of the State of New York ( “Everon”), Cleveland BioLabs, Inc., a corporation organized and existing under the laws of the State of Delaware (“CBLI,” and together with Everon, each, a “Shareholder,” and together, the “Shareholders”), and Norma Investments Limited, BVI (the “Investor”). The Company, the Shareholders and the Investor are collectively referred to herein as the “Parties.”
